C HEALTH GP(08225) officially launches multiple AI-RWS research projects, leading the new track of "AI+ clinical research".

C HEALTH GP (08225) announced that it recently successfully held the "AI-RWS Real World Research Summit" in Shanghai, and launched over ten AI-driven real-world research (AI-RWS) projects focusing on two prevalent mental neurological disorders in China: adolescent mental disorders and behavioral and psychological symptoms of dementia (BPSD). This marks a crucial step in the company's strategic layout in the Hong Kong stock "AI+ clinical research" track, further solidifying its leading position in the industry. 1. Academic and Research System The summit brought together 40 domestic experts in pediatric, adolescent psychiatric, and cognitive disorders in the elderly fields, and learned from Stanford University, Mayo Clinic, and the latest evidence-based guidelines from "JAMA Psychiatry" in 2024. It established an all-cycle closed-loop research system of "AI intelligent classificationpersonalized treatment path optimizationdynamic prediction of efficacy and safetyearly warning of relapse risk." This system integrates NLP, deep learning, and other technologies, combining multidimensional real-world data to provide high-level real-world evidence (RWE) tailored to the characteristics of the Chinese population for the two diseases. 2. Core Track Layout and Key Products 1. Billion-dollar track for adolescent mental disorders: Targeting over 30 million patients in China, the company launched an AI-RWS longitudinal study covering more than 30 institutions in 15 cities nationwide and over ten thousand patients. Simultaneously, real-world research on He Xin adolescents was carried out, exploring co-morbidity studies around He Xin's six combined or sequential treatments, involving He Xin A, He Xin Ai, He Xin Li, He Xin An, He Xin She, He Xin Le, as well as other He Xin new drug combinations. The company's proprietary AI algorithms provide innovative services in optimizing child mental health research plans, conducting combined drug-related research, and predicting future disease progression; the results will support the iteration of clinical diagnosis and treatment norms and the formulation of medical insurance policies. 2. Trillion-dollar track for dementia and BPSD in the elderly: The company initiated the "Starchild Program," establishing the largest and longest-followed BPSD real-world database in China, aiming to include 100,000 patients within five years. It focuses on non-pharmacological interventions, combination therapies, and provides essential data for innovative drug registration, post-market safety re-evaluation, etc. - Core clinical research of this track: The company has obtained exclusive clinical research experimental rights and real-world clinical research exclusive rights for He En Card Microchips and He En Meishan Microchips in China. - Core product of clinical research in this track, He En Card microchip nano microchip, a globally exclusive formulation eligible for national medical insurance, is a Level 1 Evidence A recommended product for treating mild to moderate dementia; utilizing VSMART patented technology, it can address swallowing difficulties, mix with liquid foods, avoid gastrointestinal reactions, and demonstrate superior therapeutic effects in patients with co-existing mental and Parkinson's disorders compared to other similar products currently available. 3. Commercialization Pathway and Future Prospects The company adopts a diversified funding model of "co-construction with scientific research hospitals+commission by pharmaceutical companies+government special projects+insurance co-payment," with individual projects expected to have values ranging from millions to billions. Leveraging platforms such as Boao Hainan and Hengqin, the company can shorten clinical research time for partner IV phases by over 30%, synchronizing research results and core product advantages with the strategies of the National Health Commission, thus gaining policy advantages. In the future, the company will focus on AI-RWS research and the development of intelligent doctor systems, strategically positioning its He Xin mental health brand, He En neurology brand, and Baimin allergic reaction brand, aiming to become a global leader in the field. It will accelerate the transformation to AI-driven clinical research services, creating more outstanding value returns for shareholders.